Yes from what I am reading research on that specific medication is inactive at this point but there are other medications in that class that is the NMDA receptor modulates that are currently under active study. You can google the search engine PubMed or Clinicaltrials.gov. I take glycine which is a compound in phase 2 FDA study under strict psychiatric supervision. I am the first person to show a response to it as a primary (stand alone antipsychotic). In the standard studies it is used as an adjunct (additional) antipsychotic agent. Although the NMDA receptor modulates have a more favorable side effect profile than the current generation of antipsychotics as in clinical study some have only shown promise have adjuncts at this point its too early to tell if they will be approved as primary antipsychotics and it will take further research to contrast them to the current generation of antipsychotics as regards efficacy but the results are promising.
BOY! You really are up on the specifics! How lucky is that? You're actually the first! Thanks for the response. Very grateful!